skip to content

Tony Rosenberg

Senior Advisor

Tony Rosenberg is a Senior Advisor at PJT Partners.

Prior to joining PJT Partners in 2016, Mr. Rosenberg served as Global Head, M&A and Licensing at Novartis. In this role, he managed the Novartis portfolio transformation transactions, such as forming Consumer Health JV with GSK, acquiring GSK Oncology business, selling Vaccines to GSK and CSL, selling Animal Health to Eli Lilly and Diagnostics to Grifols. Mr. Rosenberg joined Novartis via predecessor company Sandoz. He first joined Sandoz in the UK in 1980 where he held various leadership positions in sales and marketing, business development and strategic planning. In 2000, he was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma). In this role, Mr. Rosenberg managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions.

Mr. Rosenberg is currently Charmain of the Board at Cullinan Therapeutics and Oculis SA and a Board Member at argenx BX. He is also former Board member at Idenix, Clinical Ink, Radius and TriNetX

Mr. Rosenberg received a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.